Mark J. Niciu, M.D., Ph.D.

Mark J. Niciu, M.D., Ph.D.
Assistant Professor
Research focus: 

The Niciu lab is interested in the pathophysiology and experimental therapeutics of major mood and substance use disorders, especially racemic ketamine and its metabolites in treatment-refractory depression.


W267 GH


2310E-2 PBDB

Our clinical and translational research group seeks to better understand the pathophysiology and therapeutics of major mood and substance use disorders including their comorbidity. A major focus has been the identification, replication, and dissemination of biomarkers of treatment response to the glutamate modulator ketamine. As an example, our group and others have demonstrated that a history of an alcohol use disorder in an immediate family member is a positive predictor of antidepressant response to ketamine. Based on this observation, we are attempting to identify alcohol-sensitive biomarkers of antidepressant efficacy to ketamine and potentially other glutamate-based antidepressants. We take a multimodal approach to this work across several levels of analysis – genetics, stem-cell based models, neuroimaging, neurophysiology and psychology/behavioral testing – with the goal of translation to improve the lives of our patients and their families with these disabling disorders.

Research mode: 

Apply Now

Learn from
top-notch researchers
at the University of Iowa